An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat in Patients With Usher Syndrome Type 1B
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Oct 2019
Price : $35 *
At a glance
- Drugs SAR 421869 (Primary)
- Indications Usher syndromes
- Focus Adverse reactions
- Sponsors Sanofi
- 02 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2019 Planned End Date changed from 15 Jan 2036 to 2 Nov 2033.
- 12 Apr 2019 Planned primary completion date changed from 15 Jan 2036 to 2 Nov 2033.